Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 27, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Improved NYVAC-based vaccine vectors.

Karen V Kibler¹, Carmen E Gomez, Beatriz Perdiguero

¹The Biodesign Institute at Arizona State University, Tempe, Arizona, United States of America.

|November 19, 2011

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adenosine deaminase co-immunization reverses age-associated immunosenescence by restoring germinal center T follicular helper cell function.

bioRxiv : the preprint server for biology·2026

Same author

Early immune events during SARS-CoV-2 infection impact memory T and B cell responses.

Communications biology·2026

Same author

Characterization of a transmembrane-activating STING agonist using genetically humanized mice.

Cell reports·2026

Same author

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection.

Frontiers in immunology·2026

Same author

Macrophage-derived extracellular vesicles promote T cell-dependent inflammatory pain resolution.

bioRxiv : the preprint server for biology·2026

Same author

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.

Nature microbiology·2026

Researchers developed improved vaccinia virus vaccine vectors, NYVAC-C-KC and NYVAC-C-KC-ΔB19R, for HIV/AIDS vaccines. These novel vectors show enhanced antigen expression and replication in human cells while maintaining safety.

Area of Science:

Virology
Vaccinology
Immunology

Background:

The development of an effective HIV/AIDS vaccine remains a global health priority.
The prime-boost strategy using poxvirus and protein vaccines, as tested in the Thai trial (RV144), shows promise but requires further optimization.
Novel vaccine vectors are needed to enhance immunogenicity and efficacy against HIV/AIDS.

Purpose of the Study:

To engineer novel vaccinia virus (NYVAC) vaccine vectors with enhanced functional properties for potential HIV/AIDS vaccine applications.
To improve antigen expression and immunogenicity of the NYVAC vector system.
To assess the safety and biological characteristics of the modified NYVAC vectors.

Main Methods:

Generation of modified NYVAC vectors (NYVAC-C-KC and NYVAC-C-KC-ΔB19R) by re-incorporating host range genes (K1L, C7L) and deleting an immunomodulatory gene (B19R).

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Related Experiment Videos

Last Updated: May 27, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Evaluation of biological characteristics including antigen expression levels, replication competency in human keratinocytes and dermal fibroblasts, and virus spread in tissues.

Assessment of the safety profile, specifically the attenuation of replication-competent viruses.

Main Results:

The novel NYVAC vectors exhibited higher levels of antigen expression in infected cells compared to parental strains.
NYVAC-C-KC and NYVAC-C-KC-ΔB19R demonstrated replication-competency in human keratinocytes and dermal fibroblasts.
These modified vectors showed limited virus spread in tissues while maintaining a highly attenuated phenotype, indicating a favorable safety profile.

Conclusions:

The engineered NYVAC-C-KC and NYVAC-C-KC-ΔB19R vectors possess enhanced biological characteristics, including improved antigen expression and controlled replication.
These novel vectors represent promising candidates for further development in prime-boost vaccine strategies against HIV/AIDS.
The modified vectors maintain a safe, attenuated phenotype, supporting their potential for clinical applications in vaccine development.